Share This Profile
Share this profile on Facebook.
Link to this profile on LinkedIn.
Tweet this profile on Twitter.
Email a link to this profile.
See other services through which you can share this profile.
This profile was last updated on 12/1/14  and contains information from public web pages and contributions from the ZoomInfo community.

Dr. Bruce D. Weintraub

Wrong Dr. Bruce D. Weintraub?

President and Chief Executive Off...

Trophogen Inc
9714 Medical Center Dr., Suite 1114
Rockville , Maryland 20850
United States

Company Description: Established in July 2001 by Toucan Capital, Trophogen is a start-up biotechnology company based in Rockville, Maryland. Trophogen was formed by two molecular...   more

Employment History

  • Chief Scientific Officer
    Trophogen Inc
  • President, Chief Operating Officer and CSO
    Trophogen Inc
  • Director of the Endocrinology Training Program
    National Institutes of Health
  • Chief of Molecular and Cellular Endocrinology Branch
    National Institutes of Health
  • President
    Maryland Endocrine Society
  • Director of the Thyroid Cancer Program
    Greenebaum Cancer Center
  • Chief of the Laboratory of Molecular Endocrinology
    Institute of Human Virology of the University of Maryland Biotechnology Institute
  • Assistant Professor
    Harvard University
  • Professor of Medicine
    University of Maryland at Baltimore


  • MD
  • BA
    Princeton University
  • BA
    MDfrom Harvard University
22 Total References
Web References
Organization: Trophogen Inc. Improving Human and Animal Health With Protein Engineering., 3 Sept 2014 [cached]
Bruce D. Weintraub, MD President & CEO
Dr. Weintraub has more than 30 years experience in a biomedical research career that has focused on molecular, cellular, clinical and therapeutic aspects of glycoprotein hormones, related growth factors, thyroid hormone and their receptors. He is the author of over 300 scientific papers, reviews and book chapters. In addition has several issued and pending patents related to the cloning of the human TSH beta subunit, development of recombinant TSH, and development of superactive analogs of TSH, gonadotropins and related cystine knot growth factors. He is well known for his basic science work related to pituitary and recombinant TSH synthesis, glycosylation and action, affinity chromatography as well as clinical aspects of syndromes of inappropriate TSH secretion. In addition he was among the first to recognize and define the clinical and molecular aspects of thyroid hormone resistance, TSH- producing pituitary tumors and ectopic production of placental hormones and free subunits by various tumors. He is particularly recognized for his role as coinventor, codeveloper and a leading investigator in the international clinical trials of recombinant TSH, approved by the FDA in 1998 for the diagnosis of thyroid cancer, which has revolutionized the approach world -wide to that disease.
Dr. Weintraub obtained his BA from Princeton University magna cum laude where he was elected to Phi Beta Kappa and his MD from Harvard University cum laude where he was elected to Alpha Omega Alpha. His postdoctoral clinical and basic science training were at Harvard and the National Insitutes of Health and he later served as Assistant Professor at Harvard. In 1972 he became the first Director of the NIH Endocrinology Training Program and later Chief of its Molecular and Cellular Endocrinology Branch, positions he held until 1995. In both these positions he helped train a generation of leading international academic and clinical endocrinologists. From 1996- 2001 he was Professor of Medicine at the University of Maryland at Baltimore, Chief of the Laboratory of Molecular Endocrinology of the Institute of Human Virology of the University of Maryland Biotechnology Institute and Director of the Thyroid Cancer Program of the Greenebaum Cancer Center. He has received numerous international awards and lectureships, is a member of many scientific research organizations, served on several journal editorial boards as well as on several advisory committees to NIH and various universities. He has also served on the Council of the Endocrine Society and the American Thyroid Association as well as President of the Maryland Endocrine Society.
She then joined Dr. Weintraub and Dr. Szkudlinski at the Institute of Human Virology, University of Maryland, Baltimore and contributed to the elucidation of the mechanism of activation of the TSH receptor.
Local biotech pulls NIH license., 1 Mar 2002 [cached]
Seven years ago, researchers Bruce Weintraub and Mariusz Szkudlinski were at the National Institutes of Health developing a protein technology that had wide potential to treat illness.
Today, Weintraub and Szkudlinski are executives at Trophogen, a small startup about to gain a license from NIH to develop and market the very same technology.
"It still has to be finalized, but things are progressing well," says Weintraub, Trophogen's chief scientific officer.
Toucan Capital in Bethesda urged Weintraub and Szkudlinski to form the company and pursue marketing the technology on their own.
Gaining the platform technology license would be a sweet victory for Trophogen, which plans first to develop drugs to battle infertility -- a $5 billion market worldwide, Weintraub says.
Advanced Bioscience Laboratories, 10 Jan 2012 [cached]
"Trophogen is very pleased that the lead product of its large portfolio of more potent/efficacious and longer acting human and bovine recombinant superagonist analogs will be commercialized with ABL's expert assistance," said Dr. Bruce Weintraub, President and COO of Trophogen.
Bioniche, 23 June 2010 [cached]
Dr. Bruce Weintraub, President of Trophogen commented, "It is very gratifying for Trophogen to partner with Bioniche, a world renowned leader in veterinary reproduction, to develop its recombinant superagonist technology for this market."
The Indiana Law Blog: Law/Econ. Dev. - Biotech Industry Sees Potential In Ethics Rules, 3 Feb 2005 [cached]
"I think this ban will encourage people to leave, those especially who have a lot of interaction with drug companies and are currently in a position to receive a lot of money" from private companies, said Bruce D. Weintraub, a former NIH researcher who left and co-founded Trophogen Inc. in Rockville.
Other People with the name "Weintraub":
Other ZoomInfo Searches
Accelerate your business with the industry's most comprehensive profiles on business people and companies.
Find business contacts by city, industry and title. Our B2B directory has just-verified and in-depth profiles, plus the market's top tools for searching, targeting and tracking.
Atlanta | Boston | Chicago | Houston | Los Angeles | New York
Browse ZoomInfo's business people directory. Our professional profiles include verified contact information, biography, work history, affiliations and more.
Browse ZoomInfo's company directory. Our company profiles include corporate background information, detailed descriptions, and links to comprehensive employee profiles with verified contact information.